Kura Oncology Reports Second Quarter 2021 Financial Results
Retrieved on:
Thursday, August 5, 2021
Company, Acute leukemia, Research, Head and neck cancer, U.S. Securities and Exchange Commission, Investment, Webcast, Chief medical informatics officer, Amgen, Acquisition, Novartis, NPM1, Acute myeloid leukemia, Kura (music producer), AML, Patient, Equity capital markets, IND, KMT2A, Pharmacokinetics, 5, Wells Fargo, Therapy, GLOBE, HRAS, Cancer, News, Mixed-phenotype acute leukemia, Myelodysplastic syndrome, Risk, Hand, Nasdaq, Breakthrough therapy, Safety, Head, Tipifarnib, Security (finance), Pharmaceutical industry, Lithium, Animal
ET
Key Points:
- ET
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2021 financial results and provided a corporate update. - Research and development expenses for the second quarter of 2021 were $21.1 million, compared to $13.7 million for the second quarter of 2020.
- General and administrative expenses for the second quarter of 2021 were $12.6 million, compared to $7.5 million for the second quarter of 2020.
- Net loss for the second quarter of 2021 was $33.7 million, compared to a net loss of $20.5 million for the second quarter of 2020.